72 related articles for article (PubMed ID: 1328366)
1. A health-economic comparison of diet and drug treatment in obese men with mild hypertension.
Johannesson M; Fagerberg B
J Hypertens; 1992 Sep; 10(9):1063-70. PubMed ID: 1328366
[TBL] [Abstract][Full Text] [Related]
2. Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure: effects upon plasma insulin levels and association with changes in blood pressure and serum lipids.
Fagerberg B; Berglund A; Andersson OK; Berglund G
J Hypertens; 1992 Sep; 10(9):1053-61. PubMed ID: 1328365
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
4. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group.
Reeder BA; Angel A; Ledoux M; Rabkin SW; Young TK; Sweet LE
CMAJ; 1992 Jun; 146(11):2009-19. PubMed ID: 1596850
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive effect of diet compared with drug treatment in obese men with mild hypertension.
Berglund A; Andersson OK; Berglund G; Fagerberg B
BMJ; 1989 Aug; 299(6697):480-5. PubMed ID: 2507028
[TBL] [Abstract][Full Text] [Related]
7. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
8. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
Johannesson M
J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
[TBL] [Abstract][Full Text] [Related]
10. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
11. Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group.
Joglekar SJ; Jaguste V; Nanivadekar AS
J Assoc Physicians India; 1998; Suppl 1():41-51. PubMed ID: 11233386
[TBL] [Abstract][Full Text] [Related]
12. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
13. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
[TBL] [Abstract][Full Text] [Related]
14. Women and men with hypercholesterolemia respond similarly to an American Heart Association step 1 diet.
Geil PB; Anderson JW; Gustafson NJ
J Am Diet Assoc; 1995 Apr; 95(4):436-41. PubMed ID: 7699185
[TBL] [Abstract][Full Text] [Related]
15. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
16. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3.
Gupta R; Sarna M; Thanvi J; Rastogi P; Kaul V; Gupta VP
Indian Heart J; 2004; 56(6):646-52. PubMed ID: 15751521
[TBL] [Abstract][Full Text] [Related]
18. Effects of alcohol intake and obesity on serum liver enzyme activity in obese men with mild hypertension.
Fagerberg B; Lindstedt G; Berglund G
J Intern Med; 1993 Jun; 233(6):477-84. PubMed ID: 8099118
[TBL] [Abstract][Full Text] [Related]
19. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Milne RJ; Vander Hoorn S; Jackson RT
Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
[TBL] [Abstract][Full Text] [Related]
20. A cost-benefit study of a hypertension screening and treatment program at the work setting.
Hannan EL; Graham JK
Inquiry; 1978 Dec; 15(4):345-48. PubMed ID: 152293
[No Abstract] [Full Text] [Related]
[Next] [New Search]
